

# Identification of a predictive immune-related gene expression profiling in metastatic triple-negative breast cancers after PDL-1 blockade



## Aim of our study

1. Molecular characterization of TNBC through gene-expression profiling;
2. Identification of an immune-signature predictive of antiPD-L1 therapy benefit in metastatic setting;
3. Generation of an immune score (immune signature +/- PD-L1 +/- TMB +/- TILS)
4. Validation of the identified immune score in an independent cohort of TNBC patients treated with 1-line immunotherapy

# Background

1. Experimental cohort: IMPASSION 130 trial
2. Molecular characterization of TNBC:
  - Lehmann et al.: TNBC classification (2011)
  - PAM50
1. Role of potential predictive biomarkers of immunotherapy benefit: PDL1 IHC, TMB, TILS

# Materials and methods

Collection of FFPE breast tumor blocks from IMPASSION 130;

- PanCancer 730-Immune Panel (nCounter)
- PD1-PDL-1 IHC
- TILs

